-
公开(公告)号：US11878060B2
公开(公告)日：2024-01-23
申请号：US16323319
申请日：2017-08-04
Applicant: NOVARTIS AG
Inventor： John Dominy , Robert Dunn , Scott Glaser , Mark Keating , Carla Klattenhoff , Igor Splawski
CPC classification number: A61K47/549 , A61K47/543 , C07K16/22 , C07K16/28 , C07K16/2803 , C07K16/2851 , C07K2317/24
Abstract: The present disclosure is directed to methods of immunization and methods for generating antibodies using compositions comprising cationic lipids and polynucleotide molecules, such as polyribonucleotide molecules, e.g., mRNA, which code for immunogens (e.g., a target protein or a fragment thereof).
-
公开(公告)号：US10106605B2
公开(公告)日：2018-10-23
申请号：US15180879
申请日：2016-06-13
Applicant: Novartis AG
Inventor： Joy Ghosh , Mark Anthony Rutz , Kathrin Ulrike Tissot-Daguette , Igor Splawski , Michael Roguska
Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
-
3.发明授权公开(公告)号：US09982046B2
公开(公告)日：2018-05-29
申请号：US15346026
申请日：2016-11-08
Applicant: NOVARTIS AG
Inventor： Kurt Alex Heldwein , Igor Splawski , Jennifer Brogdon , Joshua Goldstein , William Dole , John Trauger , Chonghui Zhang
IPC: A61P9/08 , A61P9/04 , A61P9/10 , A61P9/12 , A61K39/395 , C07K16/28 , A61K9/00 , A61K45/06 , C07K14/47 , A61K39/00
CPC classification number: C07K16/28 , A61K9/0019 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61P9/04 , A61P9/08 , A61P9/10 , A61P9/12 , C07K14/4726 , C07K16/2851 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
-
Patent Agency Ranking
公开(公告)号：US09988440B2
公开(公告)日：2018-06-05
申请号：US14309330
申请日：2014-06-19
Applicant: NOVARTIS AG
Inventor： Leslie Ngozi Anuna Johnson , Ute Jaeger , Yong-In Kim , Christian Carsten Silvester Kunz , Igor Splawski , Michael Roguska , Joy Ghosh , Barbara Brannetti , Michael Stefanidakis , Sha-Mei Liao
IPC: A61K39/395 , C07K16/18 , G01N33/68 , C07K16/24 , A61K39/00
CPC classification number: C07K16/18 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/24 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/40 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/6863
Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
-
公开(公告)号：US10385127B2
公开(公告)日：2019-08-20
申请号：US16130166
申请日：2018-09-13
Applicant: NOVARTIS AG
Inventor： Joy Ghosh , Mark Anthony Rutz , Kathrin Ulrike Tissot-Daguette , Igor Splawski , Michael Roguska
Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
-
公开(公告)号：US09051365B2
公开(公告)日：2015-06-09
申请号：US13716526
申请日：2012-12-17
Applicant: NOVARTIS AG
Inventor： Leslie Ngozi Anuna Johnson , Ute Jaeger , Yong-In Kim , Christian Carsten Silvester Kunz , Igor Splawski , Michael Roguska , Joy Ghosh , Barbara Brannetti , Sha-Mei Liao , Michael Stefanidakis
CPC classification number: C07K16/18 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/24 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/40 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/6863
Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
Abstract translation: 本发明涉及结合补体因子P并用于其的抗体或其抗原结合片段，以及抗因子P抗体与结合补体成分5（C5）的抗体或其抗原结合片段的组合。
-
公开(公告)号：US10407496B2
公开(公告)日：2019-09-10
申请号：US15354978
申请日：2016-11-17
Applicant: Novartis AG
Inventor： Beate Diefenbach-Streiber , Adina Eberth , Braydon Charles Guild , Yong-In Kim , Michael Roguska , Igor Splawski
IPC: C07K16/18
Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
-
公开(公告)号：US20130295102A1
公开(公告)日：2013-11-07
申请号：US13716526
申请日：2012-12-17
Applicant: Novartis AG
Inventor： Leslie Ngozi Anuna Johnson , Ute Jaeger , Yong-In Kim , Christian Carsten Silvester Kunz , Igor Splawski , Michael Roguska , Joy Ghosh , Barbara Brannetti
IPC: C07K16/18 , G01N33/68 , C07K16/24 , A61K39/395
CPC classification number: C07K16/18 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/24 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/40 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/6863
Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
-
-
-
-
-
-
-
Search Results
8
records
(took 0.024 seconds)
